Naqvi Syed, Shrestha Asis, Alzubi Marah, Alrawabdeh Jawad, Thanendrarajan Sharmilan, Zangari Maurizio, van Rhee Frits, Schinke Carolina, Al Hadidi Samer
Myeloma Center University of Arkansas for Medical Sciences Little Rock Arkansas USA.
Department of Internal Medicine University of Jordan Amman Jordan.
EJHaem. 2024 Jul 3;5(4):789-792. doi: 10.1002/jha2.971. eCollection 2024 Aug.
Talquetamab is an approved therapy for relapsed multiple myeloma. This study examined dysgeusia and weight loss occurrences, alongside investigating symptom reversibility post-treatment cessation. Dysgeusia was prevalent, persisting in 15% of patients. On average, patients lost 6% of their weight during treatment, with weight loss persisting in about half of the patients post-discontinuation. Weight loss and dysgeusia are important adverse events to consider while on talquetamab treatment. Extending dose intervals can potentially prevent such adverse events and should be studied in future prospective clinical trials.
塔奎他单抗是一种已获批用于复发多发性骨髓瘤的疗法。本研究调查了味觉障碍和体重减轻的发生情况，并研究了治疗停止后症状的可逆性。味觉障碍很常见，15%的患者持续存在。平均而言，患者在治疗期间体重减轻了6%，约一半的患者在停药后体重持续减轻。在接受塔奎他单抗治疗时，体重减轻和味觉障碍是需要考虑的重要不良事件。延长给药间隔可能会预防此类不良事件，应在未来的前瞻性临床试验中进行研究。
